Vitality Watch

Dossier pubmed observational 14-aug-2026
Human cohort, case-control, or epidemiological association

Identifying biomarkers of accelerated ageing in cancer patients from routine clinical data.

Key claim: In older cancer patients, PhenoAgeAccel from routine blood tests predicts one-year mortality and frailty better than chronological age and appears higher after systemic anti-cancer treatment, supporting its use to stratify geriatric assessment and geroprotective interventions.

Abstract

INTRODUCTION: Cancer and ageing have a bidirectional relationship: age is the strongest risk factor for cancer, and cancer and treatments can accelerate ageing. Therefore, biological age can differ from chronological age; biomarkers are needed to stratify interventions to minimise accelerated ageing. METHODS: PhenoAge was calculated from routine blood test results of patients attending a Geriatric Oncology clinic. PhenoAgeAccel was the residual from a regression of PhenoAge against age. RESULTS: Data were available for 173 patients (62% male). Mean PhenoAge was higher than age (84.3 (12.6) vs 76.2 (7.24), p < 0.001), though the two were correlated (r = 0.579, p < 0.001). Unlike age, PhenoAge and PhenoAgeAccel were associated with one-year mortality (PhenoAge OR=1.083, 95% CI: 1.038-1.136; PhenoAgeAccel OR=1.096, 95% CI: 1.047-1.155). PhenoAge correlated with Clinical Frailty Score and Timed Up and Go (CFS: Rs=0.31, p < 0.001; TUG: Rs=0.25, p < 0.005); there were no correlations with age. PhenoAgeAccel correlated with the number of CGA interventions made (Rs=0.17, p < 0.05), unlike age and PhenoAge. Patients with diabetes mellitus had a higher PhenoAgeAccel compared to those without (3.40 vs -1.71, p = 0.002). In patients receiving systemic anti-cancer treatment, patients with PhenoAgeAccel calculated pre-treatment had less age acceleration than those with PhenoAgeAccel calculated post-treatment, both overall (2.18 vs -2.87; p = 0.048) and in matched samples (n = 21, 7.76 vs -2.87, p < 0.001). CONCLUSIONS: PhenoAgeAccel is a greater predictor of risk than chronological age in older people with cancer. This makes it a promising biomarker to stratify patients for holistic geriatric assessment, dose reductions, or future geroprotective measures which could be integrated within electronic healthcare record systems.

Why this matters

PhenoAge is already a well-replicated mortality predictor in general populations; this study is one of the first to position it specifically as a decision aid in geriatric oncology, where chronological age is a notoriously weak guide to treatment tolerance. The reported post-treatment rise in PhenoAgeAccel also raises the recurring trap for this area: whether systemic anti-cancer therapy genuinely accelerates biological aging or merely perturbs the clinical analytes PhenoAge is built from.

Source

Link

Briefing card

Identifying biomarkers of accelerated ageing in cancer patients from routine clinical data.
Stage: observational · pubmed · 14-aug-2026

If you are an older adult being evaluated for cancer treatment, this cohort suggests a PhenoAge score from your routine bloods predicted one-year mortality and frailty more accurately than your age on the chart.

In older cancer patients, PhenoAgeAccel from routine blood tests predicts one-year mortality and frailty better than chronological age and appears higher after systemic anti-cancer treatment, supporting its use to stratify geriatric assessment and geroprotective interventions.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1016/j.mad.2026.112234

build build 880 · 2bcef25 · 2026-11-18